Key result
One-year atenolol reduces blood pressure by ~18% and significantly lowers resting and exercise hemodynamics.
Why the study?
The long-term haemodynamic effects of the beta-adrenoceptor blocker atenolol in essential hypertension were not well characterized.
Does atenolol improve haemodynamic parameters in men with untreated essential hypertension?
Does atenolol improve haemodynamic parameters in men with untreated essential hypertension?
Atenolol effectively lowers blood pressure in mild to moderate hypertension, but this is driven by marked reductions in heart rate and cardiac output rather than decreased peripheral resistance.
Answers are grounded in this paper and cite their sources.
Atenolol lowers BP via reduced cardiac output without resistance change; hypothesis-generating for beta-blocker haemodynamics and should not yet change practice.
1 Thirteen men with untreated essential hypertension in WHO stage I were studied on an outpatient basis to evaluate the haemodynamic long-tern effect of a new beta-adrenoceptor blocker, atenolol. 2 Oxygen consumption, heart rate, cardiac output (Cardiogreen) and intraarterial branchial pressure were recorded at rest in a supine and sitting position and during steady state work at 300, 600 and 900 kpm/min. 3 The subjects were treated with atenolol (dose 100-200 mg/day) as the sole drug for 1 year and the haemodynamic study was repeated. 4 The blood pressure was reduced approximately 18% both at rest and during exercise, the heart rate approximately 25% and the cardiac output 16% at rest supine and 27% at rest sitting. During exercise the reductions in cardiac output were approximately 20%. The calculated total peripheral resistance was not decreased compared to pretreatment values. The mean arterial pressure-heart rate product was reduced almost 40%. 5 Apart from temporary muscular fatigue during the first weeks, no side-effects were seen. 6 Atenolol is an effective blood pressure lowering drug in mild and moderate hypertension, but the drop in blood pressure is associated with marked reduction in heart rate and cardiac output at rest as well as during exercise.
No takes yet. Share an insight, caveat, or question.
Per Lund-Johansen (1976) studied untreated essential hypertension in WHO stage I (n=13). Atenolol vs. Pretreatment baseline was evaluated on Haemodynamic effects including blood pressure, heart rate, and cardiac output. Atenolol treatment for 1 year reduced blood pressure by approximately 18%, heart rate by 25%, and cardiac output by 16-27% at rest and 20% during exercise compared to pretreatment values.
Synapse has enriched 10 related papers. Consider them for comparative context: